Direct Impact

Concepts for which Gursel Aktan has direct influence:

metastatic triple-negative breast cancer
phase iii
dabrafenib monotherapy
adjuvant lapatinib
advisory consultancy
long-term survival
eribulin mesylate

External impact

Concepts related to the work of other authors for which Gursel Aktan has influence:

neoadjuvant chemotherapy
breast cancer
optimal cut-off point
dynamic instability
young women
prognostic factor
ribbon-2 trial

Prominent publications by Gursel Aktan

KOL-Index: 72 BackgroundMetastatic triple-negative breast cancer (mTNBC), an aggressive histological subtype, has poor prognosis. Chemotherapy remains standard of care for mTNBC, although no agent has been specifically approved for this breast cancer subtype. Instead, chemotherapies approved for metastatic breast cancer (MBC) are used for mTNBC (National Comprehensive Cancer Network Guidelines [NCCN] ...
Known for
Chemotherapy Subgroup | Programmed Death-Ligand 1 Pd-L1–positive | Guideline Recommendations | 2l
KOL-Index: 47 BACKGROUND: Pathologic complete response (pCR) is a common efficacy endpoint in neoadjuvant therapy trials for triple-negative breast cancer (TNBC). Previous studies have shown that pCR is strongly associated with improved long-term survival outcomes, including event-free survival (EFS) and overall survival (OS). However, the trial-level associations between treatment effect on pCR and ...
Known for
Published Trials | Survival Tnbc | Divergent Designs | Neoadjuvant Therapy
KOL-Index: 43 Pathologic complete response (pCR) following neoadjuvant therapy has been associated with improved event-free survival (EFS) and overall survival (OS) in early-stage breast cancer. The magnitude of this association varies by breast cancer subtype, yet further research focusing on subtype-specific populations is limited. Here we provide an updated and comprehensive evaluation of the ...
Known for
Efs Tnbc | Pcr Neoadjuvant | Cross-Study Variations | Substantial Improvement
KOL-Index: 39 PurposeTo determine prevalence, clinicopathological characteristics, initial treatments, and outcomes associated with low estrogen receptor (ER)-expressing invasive breast cancer.MethodsThis retrospective, non-interventional database study included patients undergoing surgery with curative intent for invasive ductal or lobular breast cancer. Patients were treated between January ...
Known for
Determine Clinicopathological | Tumors Her2 | Dfs Survival | Characteristics Initial
KOL-Index: 31 PurposeTo identify the maximum tolerated dose (MTD) and recommended Phase II dose of MEK/AKT inhibitor combination of trametinib and afuresertib.Patients and methodsEligibility criteria were advanced solid tumors, 18 years or older, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Exclusion criteria included Type 1 diabetes, active GI disease, ...
Known for
Wild-Type Melanoma | Intermittent Dosing | Combination Akt | Subsequent De-Escalation Cohorts
KOL-Index: 20 1000 Background: Pembrolizumab (pembro) monotherapy showed promising antitumor activity and manageable safety in patients (pts) with metastatic TNBC in KEYNOTE-012, -086 and -119. KEYNOTE-355 (, NCT02819518) compared pembro + chemotherapy (chemo) vs placebo (pbo) + chemo for previously untreated locally recurrent inoperable or metastatic TNBC. Methods: Pts with ≥6 ...
Known for
Table | Metastatic Tnbc | Pts Cps | Pfs Chemo
KOL-Index: 20 Background Neoadjuvant pembro + chemo had manageable safety and promising antitumor activity in participants (pts) with early TNBC in KEYNOTE-173 and I-SPY 2. KEYNOTE-522 (NCT03036488) is a pbo controlled phase III study of neoadjuvant pembro + chemo followed by adjuvant pembro in pts with early TNBC. Methods Pts with previously untreated, non-metastatic, centrally confirmed TNBC (stage T1c ...
Known for
Puma | Ypt0 | Daiichi Sankyo | Roche Advisory
KOL-Index: 19 PURPOSE: As monotherapies, eribulin (chemotherapy) and pembrolizumab (immunotherapy) have shown promise for patients with metastatic triple-negative breast cancer (mTNBC). This phase Ib/II study examined eribulin plus pembrolizumab as a potential mTNBC treatment in first-line and later-line settings. PATIENTS AND METHODS: In this open-label, single-arm, phase Ib/II study, eligible patients ...
Known for
Treatment-Emergent | Peripheral Sensory Neuropathy | Pd-L1-Positive Tumors | 167
KOL-Index: 18 The induction of CYP2C9 by dabrafenib using S-warfarin as a probe and the effects of a CYP3A inhibitor (ketoconazole) and a CYP2C8 inhibitor (gemfibrozil) on dabrafenib pharmacokinetics were evaluated in patients with BRAF V600 mutation-positive tumors. Dabrafenib single- and repeat-dose pharmacokinetics were also evaluated. S-warfarin AUC(0- ∞) decreased 37% and Cmax increased 18% with ...
Known for
Repeat‐dose Pharmacokinetics | Systemic Exposure | Interaction Potential | Hydroxy-

Medical Oncology, Merck Co., Inc., Kenilworth, NJ, USA

© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172